EUCTR2009-014870-16-FR进行中（未招募）不适用
A phase II, multicentre, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad® 50 µg and 100 µg mucoadhesive buccal tablet (MBT) applied once daily in patients to those of placebo in the prevention and treatment of chemoradion therapy-induced oral mucositis in patients with head and neck cancer
BioAlliance Pharma0 个研究点目标入组 183 人开始时间: 2009年10月19日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 183
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female
- •2.Aged >18 years
- •3.Suffering from a newly diagnosed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx histologically-confirmed and having undergone resective surgery
- •4.eligible to receive:
- •a.a continuous course of conventional external beam irradiation (IRMT eligible) with a minimum cumulative radiation dose of 50 Gy and a maximum of 70 Gy, based on a daily dosing between 1.8 and 2.2 Gy. Planned radiation treatment fields must include at least two oral tissue sites (among buccal mucosa, floor of the mouth, tongue, soft palate) with each site receiving a total of 50 Gy or a maximum of 70 Gy.
- •b.Chemotherapy consisting of standard dosing of cisplatin or carboplatin administered in standard weekly or tri-weekly cycles
- •5.Karnofsky performance scale > 60% or ECOG = 2
- •6.Screening laboratory tests
- •a.Hemoglobin = 10g/dL
- •b.White blood count = 3500 cells/mm3
- •c.Absolute neutrophil counts = 1500 cells/mm3
- •d.Direct bilirubin = 2 times Upper Limit of Normal (ULN)
- •e.Serum AST and ALT = 3 ULN
- •f.Serum creatinine = 2 mg/dL
- •g.Serum or urine pregnancy test: Negative
- •8.Women of child bearing potential must have effective contraception method (oral or device)
- •7.Signed written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Head and neck tumours of the lips, sinuses, salivary glands, or unknown primary site
- •2.Prior radiation of the head and neck area
- •3.Prior chemotherapy
- •4.Curative surgery within less than 2 weeks or more than 10 weeks prior to the initiation of RT-CT
- •5.Presence of active infectious disease
- •6.Presence of active oral infectious disease, including oropharyngeal candidiasis and/or orofacial herpes
- •7.Presence of oral mucositis
- •8.Known or suspected chronic viral diseases including HIV
- •9.Recent stroke within the last 6 months
- •10.Bradyarrhythmia (< 60 b/min), including sinus node dysfunction or AV nodal conduction block 2nd or 3rd degree.
- •11.Severe renal insufficiency (creatinine blood level > 1.5ULN)
- •12.Administration of any concomitant treatment likely to interfere with clonidine
- •13.Ongoing heavy alcohol consumption (>100g alcohol/day)
- •14.Known hypersensitivity to clonidine, history of allergy or intolerance to milk proteins or any other component of the product
- •15.Presence of severe or uncontrolled depression
- •16.Pregnant or breast-feeding women
- •17.Inability to give informed consent or comply with study requirements
- •18.Unable or unwilling to comply with follow-up visits
- •19. Participation to a clinical trial within 30 days prior to randomization and during the entire duration of the study
研究者
相似试验
进行中（未招募）
1 期
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s diseaseEUCTR2007-001014-17-HUAlfa Wassermann S.p.A.424
进行中（未招募）
不适用
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn?s disease - RETIC/03/06moderate active Crohn diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2007-001014-17-ITALFA WASSERMA424
进行中（未招募）
不适用
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s diseaseTreatment of moderate, active Crohn’s disease: induction of remission.MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2007-001014-17-DEAlfa Wassermann S.p.A.424
进行中（未招募）
1 期
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s diseaseTreatment of moderate, active Crohn’s disease: induction of remission.MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2007-001014-17-FRAlfa Wassermann S.p.A.424
进行中（未招募）
1 期
Efficacy, safety and pharmacokinetics of BI 655066 in patients with active, moderate-to-severe Crohn's disease.Crohn's diseaseEUCTR2013-002902-29-GB120